Navigation Links
Combination therapy reverses effects of portal hypertension in rats
Date:10/1/2007

A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats. The study is in the October issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

Portal hypertension is a serious complication of chronic liver disease, and a leading cause of liver transplantation and mortality. It develops when a blockage in the blood flow through the liver causes the body to develop new blood vessels to develop (through a process called angiogenesis) across the esophagus and stomach. These new vessels drain into the portal vein, worsening the portal blood pressure and contributing to the formation of life-threatening complications like esophageal varices. Prior studies have suggested that anti-angiogenic treatment might help prevent the progression of the portal hypertension syndrome.

Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) are crucial to angiogenesis, so researchers, led by Mercedes Fernandez of the IDIBAPS in Barcelona, examined the effects of VEGF and PDGF inhibitory drugs on rats with established portal hypertension, to best mimic the typical human patient. They treated portal vein-ligated rats with rapamycin (VEGF signaling inhibitor), Gleevec (PDGF signaling inhibitor) or both simultaneously, and determined the effects on hyperdynamic splanchnic circulation and portosystemic collateralization.

In rats whose portal hypertension was fully developed, the combined therapy significantly reduced splanchnic neovascularization and pericyte coverage of neovessels. The rats experienced a 40 percent decrease in portal pressure,
'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Smoking and Breast Cancer - A Deadly Combination
3. The bad combination
4. Drug Combinations May Boost Stroke Risk
5. Combination therapy to treat breast cancer
6. Combination regime may work against prostate cancer
7. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
8. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
9. Combination Therapy Effective In Improving Lung Cancer Survival
10. Combination Therapy Found To Improves Stroke Recovery
11. Combination Therapy Found To Be More Effective In Treating Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Grand Rapids, MI (PRWEB) August 30, 2014 ... Michigan residents, Forefront Dermatology is expanding with the addition ... Mich. Dr. David Hammond who has provided leading-edge skin ... practice with Forefront Dermatology. , “As a doctor, ... care they deserve. Through partnering with Forefront Dermatology, I’m ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... 30, 2014 "My wife suffered neck, ... car accident," said one of two inventors from Bethel, ... her shoulder and neck area. She tried other pillows ... and pressure, assisting in comfort and providing extra sleep." ... CRADLE to support the head, neck and back comfortably. ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... regimen in most cancer treatments. Since it is a very ... with something more comfortable for the patient. ,Now ... off the ovary and stop the production of a female ... agonist achieves a normal action, often mimicking the action of ...
... that intake of cruciferous vegetables with a high ... against bladder cancer. ... such as broccoli, cauliflower, kale, turnips, collards, Brussels ... ,They apply their anti-oxidant effect through down regulation ...
... only affects to work, sleep and performance of other activities ... memory and your concentration. ,This is the ... Saifudin Rashiq at the University of Alberta. ,As ... Multidisciplinary Pain Centre in Edmonton, Canada, the researchers studied 24 ...
... Researchers based at the National Cancer Institute and ... an antioxidant predominately found in tomatoes , does ... fact, the researchers noted an association between beta-carotene, ... risk for aggressive prostate cancer. ,It ...
... of a type of kidney malignancy called renal cancer according ... and Women's Hospital in Boston found that women and men ... were about 30 percent less likely to develop renal cell ... who drank beer, wine or liquor. ,Jung Eun ...
... the Australian National Audit Office found that the Department ... 100,000 people with tuberculosis to enter Australia but frequently ... treatment, The Australian reports. ,People with inactive ... sometimes are permitted to enter Australia if they sign ...
Cached Medicine News:Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Risk of Bladder Cancer Reduced by Broccoli and Cauliflower 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:Tomatoes are Not So Effective in Preventing Prostate Cancer 2
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Barbara,Ann Karmanos Cancer Institute's Philip A. Philip, M.D., ... outcome,of one of the largest randomized phase III ... an education session about the,future of pancreatic cancer ... annual meeting in Chicago, IL. , The clinical ...
... - Data from first Phase 3 trial presented at ... 3 trial open the door for,patient recruitment in Europe ... 2007 --,Theratechnologies (TSX: TH) reported today that 26-week data ... were presented today in Toronto at ENDO, the 89th,annual ...
Cached Medicine Technology:Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 2Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 3Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: